Table 2.
Laboratory results of COVID‐19 pneumonia patients at admission
| All patients (n = 184) | Symptomatic treatment (n = 17) | Arbidol (n = 30) | Lopinavir/ritonavir (n = 27) | Arbidol + lopinavir/ritonavir (n = 25) | Interferon (n = 41) | Interferon + lopinavir/ritonavir (n = 21) | Interferon + darunavir (n = 23) | P value | |
|---|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase (normal range 9.0‐50.0), U/L | 23.0 (15.0‐34.0) | 17.0 (13.0‐31.5) | 17.5 (13.0‐28.0) | 25.0 (19.0‐35.0) | 24.0 (19.0‐39.0) | 25.0 (14.5‐33.0) | 20.0 (15.0‐33.0) | 27.0 (16.0‐36.0) | .153 a |
| Increased | 19 (10%) | 3 (18%) | 2 (7%) | 1 (4%) | 5 (20%) | 2 (5%) | 4 (19%) | 2 (9%) | .199 b |
| Aspartate aminotransferase (normal range 15.0‐40.0), U/L | 24.0 (15.0‐34.0) | 28.0 (22.5‐31.5) | 22.5 (18.0‐31.0) | 24.0 (21.0‐35.0) | 28.0 (23.5‐50.0) | 24.0 (20.0‐31.0) | 22.0 (19.5‐33.0) | 24.0 (19.0‐33.0) | .230 a |
| Increased | 32 (17%) | 3 (18%) | 3 (10%) | 5 (19%) | 8 (32%) | 6 (15%) | 3 (14%) | 3 (13%) | .531 b |
| Leukocytes (normal range 3.5‐9.5), ×109/L | 4.7 (3.9‐5.9) | 4.4 (4.1‐6.4)0 (0%) | 4.3 (3.3‐5.5) | 5.0 (3.6‐6.1) | 4.2 (3.7‐5.2) | 5.3 (4.1‐6.7) | 4.6 (3.7‐5.2) | 5.2 (4.4‐5.9) | .320 a |
| Increased | 4 (2%) | 2 (7%) | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) | 1 (4%) | .635 b | |
| Neutrophils (normal range 1.8‐6.3), ×109/L | 2.8 (2.3‐3.8) | 2.7 (2.1‐3.8) | 2.7 (1.8‐4.0) | 2.8 (2.1‐3.9) | 2.7 (2.3‐3.5) | 3.1 (2.4‐4.2) | 3.0 (2.4‐3.7) | 3.0 (2.5‐4.0) | .825 a |
| Increased | 10 (5%) | 1 (6%) | 4 (13%) | 1 (4%) | 0 (0%) | 2 (5%) | 1 (5%) | 1 (4%) | .584 b |
| Lymphocytes (normal range 1.1‐3.2), ×109/L | 1.2 ± 0.5 | 1.3 ± 0.5 | 1.1 ± 0.4 | 1.2 ± 0.6 | 1.0 ± 0.5 | 1.4 ± 0.6 | 1.2 ± 0.4 | 1.3 ± 0.4 | .070 a |
| Decreased | 92 (50%) | 7 (41%) | 17 (57%) | 13 (48%) | 17 (68%) | 18 (44%) | 10 (48%) | 10 (44%) | .495 c |
| Erythrocyte sedimentation rate (normal range 0.0‐15.0), mm/h | 64.1 ± 36.1 | 61.8 ± 28.3 | 62.3 ± 39.2 | 70.6 ± 41.7 | 62.5 ± 29.4 | 58.8 ± 38.1 | 73.4 ± 39.2 | 63.4 ± 32.8 | .777 d |
| Increased | 169 (92%) | 15 (88%) | 25 (83%) | 23 (85%) | 22 (88%) | 34 (83%) | 20 (95%) | 20 (87%) | .916 b |
Note: Data are median (IQR), n (%) and mean ± SD. Increased means exceeding the upper limit of the normal range and decreasing means less than the lower limit of the normal range.
Abbreviations: ANOVA, analysis of variance; COVID‐19, coronavirus disease 2019; IQR, interquartile range.
a
P value comparing groups is from the Kruskal‐Wallis test.
b
P value comparing groups is from Fisher's exact test.
c
P value comparing groups is from the Pearson χ 2 test.
d
P value comparing groups is from ANOVA.